Table 1.
Demographics and clinical characteristics of the study population (n = 66 kidney transplant procedures performed in 65 patients).
Table 2.
Immunosuppression and prophylaxis regimens (n = 66 kidney transplant procedures performed in 65 patients).
Fig 1.
Temporal distribution of episodes of acute AMR in the study cohort.
AMR: antibody-mediated rejection.
Fig 2.
Description of therapeutic approaches in 75 episodes of acute AMR according to individual agents or therapies used.
AMR: antibody-mediated rejection; ATG: antithymocyte globulin (different formulations [ATG-Fresenius® or Thymoglobulin®]); IA: immunoadsorption; IVIg: intravenous immunoglobulins; PPh: plasmapheresis.
Table 3.
Clinical syndromes and causative agents of the episodes of infection occurring within the first 6 months after the diagnosis of acute AMR (n = 96).
Fig 3.
Cumulative incidence of infection within the first 6 months after the diagnosis of acute AMR in the “per-patient” analysis.
(a) overall infection according to the use of plasmapheresis as anti-rejection therapy (log-rank test P-value = 0.002); (b) bacterial infection according to the use of IVIg as anti-rejection therapy (log-rank test P-value = 0.035). The last episode was taken as reference in patients with more than one rejection episode. AMR: antibody-mediated rejection; IVIg: intravenous immunoglobulins.
Table 4.
Univariate and multivariate analyses of risk factors predicting the occurrence of overall infection within the first 6 months after the diagnosis of acute AMR in the “per-patient” analysis (i.e. the last episode was taken as reference in patients with more than one rejection episode).
Table 5.
Univariate and multivariate analyses of risk factors predicting the occurrence of bacterial infection within the first 6 months after the diagnosis of acute AMR in the “per-patient” analysis (i.e. the last episode was taken as reference in patients with more than one rejection episode).
Table 6.
Univariate and multivariate analyses of risk factors predicting the occurrence of opportunistic infection within the first 6 months after the diagnosis of acute AMR in the “per-episode” analysis (i.e. follow-up was censored at the time of diagnosis of the second or consecutive episodes in patients with more than one rejection episode).
Fig 4.
Patient (a) and death-censored graft survival (b) within the first year after the diagnosis of acute AMR in the “per-patient” analysis. The last episode was taken as reference in patients with more than one rejection episode. AMR: antibody-mediated rejection.